Minerva Neurosciences sets up $75.0 million at-the-market stock sale program with Leerink
Minerva Neurosciences entered a Sales Agreement with Leerink Partners LLC for an at-the-market offering of up to $75.0 million of common stock, with a 3.0% commission on gross proceeds. The company is not obligated to sell any shares, so the program could dilute existing shareholders if used. The filing also says the relapse assessment phase of its Phase 3 C19 trial of roluperidone was extended from 40 weeks to 52 weeks after FDA feedback, with topline results still expected in the second half of 2027.
Key points
- Up to $75.0 million of common stock may be sold through Leerink Partners LLC, under a prospectus supplement dated May 27, 2026
- Agent commission is 3.0% of gross proceeds; the company has no obligation to sell any shares
- Relapse assessment phase of the C19 trial extended from 40 weeks to 52 weeks after FDA feedback
- Topline efficacy results still expected in the second half of 2027; relapse assessment data in the second half of 2028
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.